Ion Channels: Exploiting natural regulation

Using a short peptide to regulate the activity of HCN ion channels illustrates how physiological modulators could inspire new drugs. .
  1. Catherine Proenza  Is a corresponding author
  1. University of Colorado Anschutz Medical Campus, United States

From the brain to the heart to the bladder, electrical potentials across cell membranes ensure that nerves and muscles work properly. These potentials emerge as ions go into and out of cells, crossing the membrane through proteins known as ion channels. The structures open and close their ion-conducting pores in response to voltage changes, the binding of ligands, or both.

Mutations in ion channels can lead to conditions like epilepsy or abnormal cardiac rhythms, which are caused by faulty electric signals in the brain or the heart. Drugs that target these proteins can help to treat the diseases, but they often act by blocking the pore. This means that they can inhibit but not increase the activity of the channel. Moreover, given the similarities between the pores of different types of ion channels, it is challenging to create blockers that are specific to just one type.

Nature regulates ion channels too, of course. For example, our heart beats faster during a fight-or-flight response because the body subtly alters the properties of ion channels in the pacemaker cells that set the heart rate. However, nature does not typically block pores: rather, it relies on molecules that act indirectly, via other domains of the channels. This ‘allosteric modulation’ can either activate or inhibit ion channels; it can also be more specific than pore blockade because these other domains vary considerably between different types of channels. Designing new categories of drugs with sites of action that mimic the ones found in natural allosteric regulators could help to target ion channels more accurately, and control their activity more finely.

Now, in eLife, Anna Moroni of the University of Milan, Bina Santoro at Columbia University, and colleagues at institutes in Italy, Germany and France – including Andrea Saponaro as first author – report what may constitute a first step towards developing such drugs (Saponaro et al., 2018).

Their work focuses on HCN (short for hyperpolarization-activated cyclic nucleotide-sensitive) channels, which are present both in neurons and in cardiac pacemaker cells. These channels open when the membrane potential becomes more negative, but nature also uses cyclic nucleotides such as cAMP to fine-tune the precise voltage range at which they activate. Cyclic nucleotides attach directly to a conserved sequence, the cyclic nucleotide-binding domain, which is located in an intracellular region of HCN channels; in turn, this interaction shifts the range of voltage activation to more positive potentials, making the channels easier to open with voltage.

Nearly fifteen years ago, it was found that HCN channels in neurons associate with an additional subunit called TRIP8b (Santoro et al., 2004). This protein binds to the channels at two distinct sites, which in turn modulates their activity in two different ways (Santoro et al., 2011; Han et al., 2011; Bankston et al., 2012). In one type of regulation, an end of TRIP8b associates with one of the extremities of the channels to control how many channels are expressed on the membrane. In the other type, the central core region of TRIP8b attaches to the cyclic nucleotide-binding domain to decrease the sensitivity of the channel to cAMP.

Building on previous research, Saponaro et al. characterize the interactions between TRIP8b and HCN channels that are required to lessen their response to cAMP. Using a combination of techniques (NMR, structural modeling, and calorimetry) they reveal that a short peptide containing 40 amino acids, TRIP8bnano, attaches to the cyclic nucleotide-binding domain and is enough to reduce the affinity of the channel for cAMP.

The interactions between TRIP8bnano and the cyclic nucleotide-binding domain were found to be mainly electrostatic, as previously suggested (DeBerg et al., 2015). Many, but not all, of the residues that associate with TRIP8bnano also interact with cAMP. This observation supports previous claims that the channels reduce their affinity for cAMP in two ways. First, TRIP8b and the nucleotide directly compete with each other (Han et al., 2011; DeBerg et al., 2015; Bankston et al., 2017); second, when TRIP8b binds, it indirectly causes rearrangements in the cyclic nucleotide-binding domain that make it more difficult for cAMP to attach (Hu et al., 2013; Saponaro et al., 2014; DeBerg et al., 2015).

An important set of experiments also showed that the TRIP8bnano peptide can prevent cAMP from regulating HCN channels which are both native (in cardiac pacemaker cells) and artificially expressed (in propagated cell lines). In fact, even though TRIP8b is not expressed in the heart, the peptide can still slow the rate at which pacemaker cells fire; in principle, this could be used to design better drugs to decrease heart rate. As the interaction between HCN channels and TRIP8b has also been associated with depression (Lyman et al., 2017) and active coping behavior (Fisher et al., 2018), these results may be of interest in the treatment of mental health disorders as well.

The work by Saponaro et al. is a proof of concept that small regions of natural allosteric regulators can be exploited to modify the activity of ion channels in cells. Ultimately, it underscores how pinpointing regulatory hotspots on these channels could power the creation of new allosteric drugs.


Article and author information

Author details

  1. Catherine Proenza

    Catherine Proenza is in the Department of Physiology and Biophysics and the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, United States

    For correspondence
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4324-6206

Publication history

  1. Version of Record published: August 6, 2018 (version 1)


© 2018, Proenza

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 936
    Page views
  • 77
  • 3

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Catherine Proenza
Ion Channels: Exploiting natural regulation
eLife 7:e39664.

Further reading

    1. Structural Biology and Molecular Biophysics
    Xiaoxuan Lin, Patrick R Haller ... Tobin R Sosnick
    Research Article

    Prestin responds to transmembrane voltage fluctuations by changing its cross-sectional area, a process underlying the electromotility of outer hair cells and cochlear amplification. Prestin belongs to the SLC26 family of anion transporters yet is the only member capable of displaying electromotility. Prestin’s voltage-dependent conformational changes are driven by the putative displacement of residue R399 and a set of sparse charged residues within the transmembrane domain, following the binding of a Cl anion at a conserved binding site formed by the amino termini of the TM3 and TM10 helices. However, a major conundrum arises as to how an anion that binds in proximity to a positive charge (R399), can promote the voltage sensitivity of prestin. Using hydrogen–deuterium exchange mass spectrometry, we find that prestin displays an unstable anion-binding site, where folding of the amino termini of TM3 and TM10 is coupled to Cl binding. This event shortens the TM3–TM10 electrostatic gap, thereby connecting the two helices, resulting in reduced cross-sectional area. These folding events upon anion binding are absent in SLC26A9, a non-electromotile transporter closely related to prestin. Dynamics of prestin embedded in a lipid bilayer closely match that in detergent micelle, except for a destabilized lipid-facing helix TM6 that is critical to prestin’s mechanical expansion. We observe helix fraying at prestin’s anion-binding site but cooperative unfolding of multiple lipid-facing helices, features that may promote prestin’s fast electromechanical rearrangements. These results highlight a novel role of the folding equilibrium of the anion-binding site, and help define prestin’s unique voltage-sensing mechanism and electromotility.

    1. Neuroscience
    2. Structural Biology and Molecular Biophysics
    Megan M Cullinan, Robert C Klipp ... John R Bankston
    Research Article

    Acid-sensing ion channels (ASICs) are trimeric proton-gated sodium channels. Recent work has shown that these channels play a role in necroptosis following prolonged acidic exposure like occurs in stroke. The C-terminus of ASIC1a is thought to mediate necroptotic cell death through interaction with receptor interacting serine threonine kinase 1 (RIPK1). This interaction is hypothesized to be inhibited at rest via an interaction between the C- and N-termini which blocks the RIPK1 binding site. Here, we use two transition metal ion FRET methods to investigate the conformational dynamics of the termini at neutral and acidic pH. We do not find evidence that the termini are close enough to be bound while the channel is at rest and find that the termini may modestly move closer together during acidification. At rest, the N-terminus adopts a conformation parallel to the membrane about 10 Å away. The distal end of the C-terminus may also spend time close to the membrane at rest. After acidification, the proximal portion of the N-terminus moves marginally closer to the membrane whereas the distal portion of the C-terminus swings away from the membrane. Together these data suggest that a new hypothesis for RIPK1 binding during stroke is needed.